S
Sarju Ganatra
Researcher at Lahey Hospital & Medical Center
Publications - 103
Citations - 3255
Sarju Ganatra is an academic researcher from Lahey Hospital & Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 55 publications receiving 1625 citations. Previous affiliations of Sarju Ganatra include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
Myocarditis in patients treated with immune checkpoint inhibitors
Syed S. Mahmood,Michael G. Fradley,Justine V. Cohen,Anju Nohria,Kerry L. Reynolds,Lucie Heinzerling,Ryan J. Sullivan,Rongras Damrongwatanasuk,Carol L. Chen,Dipti Gupta,Michael C. Kirchberger,Magid Awadalla,Malek Z.O. Hassan,Javid Moslehi,Sachin P. Shah,Sarju Ganatra,Paaladinesh Thavendiranathan,Donald P. Lawrence,John D. Groarke,Tomas G. Neilan +19 more
TL;DR: Myocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.
Journal ArticleDOI
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano,Daniel J. Lenihan,Michael G. Fradley,Sarju Ganatra,Ana Barac,Anne H. Blaes,Jörg Herrmann,Charles B. Porter,Alexander R. Lyon,Patrizio Lancellotti,Aarti Patel,Jeanne M. DeCara,Joshua D. Mitchell,Eric E. Harrison,Javid Moslehi,Ronald M. Witteles,Maria Grazia Calabrò,Roberto Orecchia,E. de Azambuja,J. L. Zamorano,Ron Krone,Zaza Iakobishvili,Joseph R. Carver,Saro H. Armenian,Bonnie Ky,Daniela Cardinale,Carlo M. Cipolla,Susan Dent,Karin Jordan +28 more
TL;DR: Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment, and guidance regarding prevention, screening, monitoring and treatment of CV toxicity is provided.
Journal ArticleDOI
Immune Checkpoint Inhibitor-Associated Myocarditis.
Sarju Ganatra,Tomas G. Neilan +1 more
TL;DR: A clinical vignette is described and the salient features and management strategies of ICI-associated myocarditis are discussed, which typically occurs early, with an elevated troponin, may present with an normal left ventricular ejection fraction and may have a fulminant course.
Journal ArticleDOI
Cardiovascular magnetic resonance in immune checkpoint inhibitor-Associated myocarditis
Lili Zhang,Magid Awadalla,Syed S. Mahmood,Anju Nohria,Malek Z.O. Hassan,Franck Thuny,Daniel A. Zlotoff,Sean P. Murphy,James R. Stone,Doll Lauren Alexandra Golden,Raza M. Alvi,Adam Rokicki,Maeve Jones-O'Connor,Justine V. Cohen,Lucie Heinzerling,Connor P. Mulligan,Merna Armanious,Ana Barac,Brian J. Forrestal,Ryan J. Sullivan,Raymond Y. Kwong,Eric H. Yang,Rongras Damrongwatanasuk,Carol L. Chen,Dipti Gupta,Michael C. Kirchberger,Javid Moslehi,Otavio R. Coelho-Filho,Sarju Ganatra,Muhammad A. Rizvi,Gagan Sahni,Carlo G. Tocchetti,Valentina Mercurio,Michael Mahmoudi,Donald P. Lawrence,Kerry L. Reynolds,Jonathan W. Weinsaft,Jonathan W. Weinsaft,A. John Baksi,Stéphane Ederhy,John D. Groarke,Alexander R. Lyon,Michael G. Fradley,Paaladinesh Thavendiranathan,Tomas G. Neilan +44 more
TL;DR: The CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented and caution is suggested in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI.
Journal ArticleDOI
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Magid Awadalla,Syed S. Mahmood,John D. Groarke,Malek Z.O. Hassan,Anju Nohria,Adam Rokicki,Sean P. Murphy,Nathaniel D. Mercaldo,Lili Zhang,Daniel A. Zlotoff,Kerry L. Reynolds,Raza M. Alvi,Dahlia Banerji,Shiying Liu,Lucie Heinzerling,Maeve Jones-O'Connor,Rula Bany Bakar,Justine V. Cohen,Michael C. Kirchberger,Ryan J. Sullivan,Dipti Gupta,Connor P. Mulligan,Sachin P. Shah,Sarju Ganatra,Muhammad A. Rizvi,Gagan Sahni,Carlo G. Tocchetti,Donald P. Lawrence,Michael Mahmoudi,Richard B. Devereux,Brian J. Forrestal,Anant Mandawat,Alexander R. Lyon,Carol L. Chen,Ana Barac,Judy Hung,Paaladinesh Thavendiranathan,Michael H. Picard,Franck Thuny,Stéphane Ederhy,Michael G. Fradley,Tomas G. Neilan +41 more
TL;DR: GLS decreases with ICI myocarditis and, compared with control subjects, was lower among cases presenting with either a preserved or reduced EF, and the risk of MACE was higher with a lower GLS among patients witheither a reduced or preserved EF.